SystImmune, Inc. (SystImmune), a clinical-stage biotechnology company, today announced that one abstract on izalontamab brengitecan (iza-bren), a potentially first-in-class EGFRxHER3 bispecific antibody drug conjugate (ADC) will be presented at the European Society for Medical Oncology (ESMO) Breast Cancer 2025 Annual Congress taking place May 14 – May 17 in Munich, Germany. Iza-bren is being jointly developed by SystImmune and Bristol Myers Squibb under a collaboration and exclusive license agreement.
Data will be presented at the meeting from an ongoing Ph1 clinical trial of iza-bren in patients with locally advanced or metastatic HER2- Breast Cancer. Additional subgroup analysis in previously disclosed data at SABCS 2024 shows encouraging efficacy for iza-bren across all HER2 levels in HER2- Breast Cancer patients including HER2 0 patients. These data highlights continued progress in iza-bren clinical development and builds upon the previously reported clinical data in breast cancer patients at SABCS in 2024.
“These data continue to support our conviction that iza-bren demonstrates strong clinical efficacy across a wide variety of tumors such as breast cancer including HER2 negative breast cancer with a manageable safety profile,” said Jonathan Cheng, M.D., CMO of SystImmune. “This positions iza-bren as an important therapeutic option that may address the unmet medical needs of patients with limited treatment options. We are committed to advancing this therapy through clinical trials, exploring its potential not only as a monotherapy but also in combination with other agents, so as to improve outcomes for cancer patients globally.”
